- Home
- RPRX vs FFIV Comparison
RPRX vs FFIV Comparison
Compare RPRX & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- FFIV
- Stock Information
- Founded
- RPRX 1996
- FFIV 1996
- Country
- RPRX United States
- FFIV United States
- Employees
- RPRX N/A
- FFIV N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- FFIV Computer Communications Equipment
- Sector
- RPRX Health Care
- FFIV Telecommunications
- Exchange
- RPRX Nasdaq
- FFIV Nasdaq
- Market Cap
- RPRX 14.2B
- FFIV 14.8B
- IPO Year
- RPRX 2020
- FFIV 1999
- Fundamental
- Price
- RPRX $31.03
- FFIV $241.61
- Analyst Decision
- RPRX Strong Buy
- FFIV Hold
- Analyst Count
- RPRX 5
- FFIV 10
- Target Price
- RPRX $41.60
- FFIV $289.00
- AVG Volume (30 Days)
- RPRX 4.7M
- FFIV 545.6K
- Earning Date
- RPRX 05-08-2025
- FFIV 04-28-2025
- Dividend Yield
- RPRX 2.77%
- FFIV N/A
- EPS Growth
- RPRX N/A
- FFIV 31.07
- EPS
- RPRX 1.91
- FFIV 10.05
- Revenue
- RPRX $2,263,576,000.00
- FFIV $2,890,012,000.00
- Revenue This Year
- RPRX $34.04
- FFIV $9.02
- Revenue Next Year
- RPRX $6.10
- FFIV $4.01
- P/E Ratio
- RPRX $16.63
- FFIV $25.29
- Revenue Growth
- RPRX N/A
- FFIV 3.02
- 52 Week Low
- RPRX $24.05
- FFIV $159.01
- 52 Week High
- RPRX $34.20
- FFIV $313.00
- Technical
- Relative Strength Index (RSI)
- RPRX 36.17
- FFIV 28.97
- Support Level
- RPRX $30.82
- FFIV $259.00
- Resistance Level
- RPRX $31.85
- FFIV $274.54
- Average True Range (ATR)
- RPRX 0.76
- FFIV 6.97
- MACD
- RPRX -0.25
- FFIV -1.56
- Stochastic Oscillator
- RPRX 9.57
- FFIV 6.14
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.